Uncategorized

3 Monster Stocks to Buy Right Now With Dividend Yields of 5% or More

What’s the yield of the Vanguard High Dividend Yield ETF (NYSEMKT: VYM)? Only 2.2%. That qualifies as a high yield for some investors these days.

But investors hoping to generate more income have other alternatives that offer much juicier yields. Here are three monster stocks to buy right now with dividend yields of 5% or more.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »

Die spelling "YIELD" on top of five increasingly higher stacks of coins.
Image source: Getty Images.

1. Enterprise Products Partners

Enterprise Products Partners (NYSE: EPD) sports a lofty forward distribution yield of 6.1%. Even better, the limited partnership (LP) has increased its distribution for 27 consecutive years. Enterprise appears to be in a good position to keep that streak going.

The company operates over 50,000 miles of pipelines that transport natural gas liquids (NGLs), crude oil, petrochemicals, and other refined products throughout much of the U.S. Enterprise Products Partners also owns midstream energy assets, including liquids storage facilities, fractionators, and natural gas processing trains.

There’s a good case to be made that Enterprise Products Partners is the best pipeline stock on the market. It boasts the highest credit rating in the midstream space, reflecting the LP’s strong balance sheet. Enterprise has also delivered an average return on invested capital of 12% over the last 10 years.

You might even be surprised by Enterprise Products Partners’ growth prospects. Multiple factors are driving increased demand for natural gas and NGLs, including overall economic growth and the rapid expansion of data center infrastructure. Enterprise is preparing to capitalize on these opportunities, with $5.3 billion of major capital projects under construction.

2. Pfizer

Pfizer (NYSE: PFE) offers one of the most attractive dividends in the healthcare sector, yielding around 7.2%. The big drugmaker has paid a dividend for 350 consecutive quarters, with the 351st due in September.

Few companies have a broader product lineup than Pfizer. It markets over a dozen blockbuster products, including cancer therapies, primary care drugs, specialty drugs, and vaccines. Pfizer’s pipeline features 96 programs, 36 of which are either awaiting regulatory approval or in late-stage testing.

To be sure, Pfizer faces a daunting patent cliff over the next couple of years. Adcetris and Xeljanz lose U.S. patent exclusivity this year. Eliquis, Ibrance, and Xtandi follow suit in 2027. The company also experienced a recent setback with sigvotatug vedotin failing to meet the primary endpoint in a phase 3 study targeting previously treated non-small cell lung cancer (NSCLC).

Source link

Visited 1 times, 1 visit(s) today

Leave a Reply

Your email address will not be published. Required fields are marked *